Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941798 · ClinicalTrials.gov registry record · Phase 2
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,283
- Enrollment target
NCT00941798 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,283 participants.
The verdict
NCT00941798, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,283 participants
- Enrollment target
Study Summary
Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial was to assess the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This was an event driven trial.
Interventions
- DRUG QMF149 Twisthaler®
- DRUG Mometasone Twisthaler®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,283 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00941798
The ClinicalTrials.gov registry entry for NCT00941798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QMF149 Twisthaler® is the first listed.
NCT00941798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00941798 about?
NCT00941798 is a clinical study titled "Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma". Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial wa...
What is the current status of trial NCT00941798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,283 participants. The study started on 2009-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00941798?
The interventions under investigation include: QMF149 Twisthaler® (DRUG), Mometasone Twisthaler® (DRUG).
Who is sponsoring clinical trial NCT00941798?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.